ENOVA is a science and technology “Network on Vaccine Adjuvants”, funded by COST through the EU Framework Programme Horizon 2020. ENOVA is coordinated by the Vaccine Formulation Institute (UK) and brings together European experts and stakeholders working in different areas of adjuvant and vaccine R&D, including both prophylactic and therapeutic applications as well as human and veterinary vaccines. ENOVA’s members include industry, academic, and government institutions. The ultimate goals of the network are to facilitate communication and the exchange of information among its membership, to ensure that new discoveries are widely disseminated so that their potential can be of optimal benefit, to promote the best use of existing adjuvant technologies, and to encourage and support the development of novel adjuvants.
1st call for ENOVA training school
Sep. 29, 2018 12:39 PM
ENOVA Adjuvants and Vaccine Formulation Training School
25th to 28th March 2019, University of Geneva, Switzerland
Deadline for applications to be submitted: November 1st, 2018
Call information and application procedure can be found here
2nd Call for STSM Applications
Sep. 12, 2018 1:04 PM
COST ENOVA Call Number 2 for Short Term Scientific Missions (STSM) Applications
Deadline for applications to be submitted: 30 / 09 / 2018 Notification of application outcome: 2018-10-12 Period of STSM: between 22 / 10 / 2018 and 15 / 03 / 2019
Call information and application procedure can be found here.
Open call for Vaccine Development Services
July 3, 2018 2:02 PM
TRANSVAC: European Vaccine Research and Development Infrastructure - next cut-off date for proposal submission is on 15 August 2018
First call for training modules. Deadline 1 July 2018
June 6, 2018 2:07 PM
The f irst call for training modules has been launched, the deadline for application is 1 July 2018.
Training scientists in vaccine research and development (R&D) is crucial in order to sustain Europe’s excellence in this field. The TRANSVAC2 Consortium has set up training modules at leading European centers that can be combined to create customised international courses on vaccine R&D. Two rounds of customised training courses are planned. Participants can select topics as needed in their field of vaccine development and the timelines of the various modules are harmonized in a way that allows a logical continuation from one topic to the other.
ENOVA press release
May 28, 2018 5:00 PM
European collaboration for developing vaccine adjuvants